Skip to main content
LCTX
NYSE Life Sciences

Lineage Closes NeuroAirmid Buy, Adding Clinical-Stage Huntington's Program HUNT1

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.99
Mkt Cap
$250.454M
52W Low
$0.882
52W High
$1.99
52W Position info
12% above low
Off High info
50% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

LCTX is trading near its 52-week low of $0.882 (12% above the low).

Summary

Lineage acquired NeuroAirmid and its clinical-stage HUNT1 Huntington's disease cell therapy for about $4.7 million upfront, with up to $48 million in milestone payments and most trial costs covered by a CIRM grant. Q3 cash of $45.2 million is expected to fund operations into Q2 2028.


Key Events · M&A and Partnerships · LCTX

  • NeuroAirmid Acquisition Closed

    Lineage acquired 100% of NeuroAirmid on November 12, 2026, adding HUNT1 (hNSC-01), a pluripotent stem cell-derived neural cell therapy in a Phase 1b/2a Huntington's disease trial (REGEN4HD) with 6 patients dosed to date.

  • Deal Economics: $4.7M Upfront, $48M Milestones

    Closing consideration was $2.4 million cash plus 2.2 million LCTX shares (calculated as $2.1 million divided by the 20-day VWAP), a $0.2 million expense fund and $1.7 million to settle NeuroAirmid obligations. Up to $5.4 million is due on the first anniversary and up to $48.0 million in aggregate upon clinical and regulatory milestones.

  • CIRM Covers Most Trial Costs

    The REGEN4HD study is supported by a CIRM award of up to $12 million; Lineage is responsible for up to $3.1 million of co-funding through February 2030, limiting out-of-pocket development spend.

  • Dilution and Resale Registration

    The 2.2 million shares issued at closing were unregistered; Lineage agreed to file a resale registration statement within 60 days and seek effectiveness within 90 days. Up to roughly 50% of post-closing payments may be settled in stock, subject to NYSE American limits.


Analysis · LCTX · Life Sciences

Lineage acquired NeuroAirmid and its HUNT1 neural stem cell program—already dosing patients in a Phase 1b/2a Huntington's disease trial—for roughly $4.7 million at closing, split about evenly between cash and stock. That is a cheap way to add a third clinical-stage asset: the upfront is small, most of the consideration is deferred ($5.4 million on the first anniversary) or contingent (up to $48 million in milestones), and CIRM grant money covers most of the ongoing trial cost, leaving Lineage on the hook for only about $3.1 million through February 2030. The trade-off is dilution: 2.2 million shares were issued at closing, up to half of future payments may be settled in stock, and the sellers get resale registration within 60 days. The same-day Q3 release shows $45.2 million in cash with runway into Q2 2028 and a $4.2 million quarterly profit that is entirely a non-cash warrant mark-to-market gain, not operations.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LCTX was trading at $0.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $250.5M. The 52-week trading range was $0.88 to $1.99. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LCTX - Latest Insights